|Advances in the treatment of HIV/AIDS with HIV-1 protease inhibitors in combination with reverse transcriptase inhibitors, known as highly active antiretroviral therapy (HAART), has resulted in improved life expectancy and significantly reduced HIV/AIDS-related mortality in the developed world. Unfortunately, HAART suffers from adverse drug side effects, poor oral bioavailability, and drug interactions. Also, drug-resistant HIV-1 variants have begun to emerge. Development of antiretroviral therapy with broad-spectrum activity and minimal side effects is needed for current and future HIV/AIDS treatment.
Purdue University researchers have created Darunavir, brand name Prezista, a drug used to treat HIV infection. Prezista was developed by the pharmaceutical company Tibotec and is an OARAC recommended treatment option for treatment-naive and treatment-experienced adults and adolescents. It is also used in patients with drug-resistant HIV.
The researchers have also developed a new generation of protease inhibitors that are exceedingly potent and maintain potency against multidrug resistant HIV-1 variants. Dr. Ghosh's laboratory has designed, synthesized, and evaluated several different series of compounds. These novel protease inhibitors show potent enzyme inhibitory, antiviral activity, and exceptional broad spectrum activity against highly cross-resistant mutant.
-Decreased adverse side effects
-Effective against multidrug resistant HIV-1 variants
-Superior pharmacokinetic properties
Jan 6, 2011
Aug 6, 2013
Jul 8, 2009
Jul 8, 2009
Jul 9, 2008
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486